Virus detection and duration of illness among patients with 2009 pandemic influenza a (H1N1) virus infection in Texas

Clinical Infectious Diseases

Volumn 52, Issue SUPPL. 1, 2011, Pages

  Suryaprasad, Anil ^a,b   Morgan, Oliver W ^a,c   Peebles, Patrick ^d   Warner, Agnes ^d   Kerin, Tara K ^d   Esona, Mathew D ^d   Bowen, Michael D ^d   Sessions, Wendy ^d   Xu, Xiyan ^d   Cromeans, Theresa ^d   Dawood, Fatimah ^a,d   Shim, Trudi ^e   Menon, Manoj ^a   Verani, Jennifer R ^d   Erdman, Dean ^d   Lindstrom, Stephen ^d   Fonseca, Vincent P ^e   Fry, Alicia M ^d   Olsen, Sonja J ^c  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b INDIAN HEALTH SERVICE   (United States)

^c NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^d NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^e TEXAS DEPARTMENT OF STATE HEALTH SERVICES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OSELTAMIVIR; VIRUS RNA; ZANAMIVIR;

2009 H1N1 INFLUENZA; ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; DISEASE DURATION; FECES ANALYSIS; FEVER; HUMAN; INFANT; INFLUENZA VIRUS A H1N1; PANDEMIC; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; UNITED STATES; VIRUS CULTURE; VIRUS DETECTION;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; COUGH; FECES; FEMALE; FEVER; HUMANS; INFANT; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MALE; MIDDLE AGED; NASOPHARYNX; PANDEMICS; PREGNANCY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TEXAS; TIME FACTORS; VIRUS CULTIVATION; VIRUS SHEDDING; YOUNG ADULT;

EID: 79953755935     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciq014     Document Type: Article

References (27)

1. Chan M. World now at the start of 2009 influenza pandemic. Geneva: World Health Organization; 2009. Available from: http://www.who.int/mediacentre/news/ statements/2009/h1n1-pandemic-phase6-20090611/en/index.html. Accessed February 19, 2010.
2. Centers for Disease Control and Prevention. CDC recommendations for the amount of time persons with influenza-like illness should be away from others. Atlanta: US Department of Health and Human Services, CDC; 2009. Available from: http://www.cdc.gov/h1n1flu/guidance/exclusion.htm. Accessed February 19, 2010.
3. Carrat F, Vergu E, Ferguson NM, et al. Timelines of infection and disease in human influenza: a review of volunteer challenge studies. Am J Epidemiol 2008; 167:775-785. (Pubitemid 351451744)
4. Novel Swine-Origin Influenza A Virus Investigation Team. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 2009; 360:2605-2615.
5. Maines TR, Jayaraman A, Belser JA, et al. Transmission pathogenesis of swine-origin 2009 A (H1N1) influenza viruses in ferrets and mice. Science. 2009; 325:484-487.
6. To KK, Chan KH, Li IW, et al. Viral load in patients infected with pandemic H1N1 2009 influenza A virus. J Med Virol. 2009; 82:1-7.
7. Centers for Disease Control and Prevention. CDC protocol of real-time RTPCR for swine influenza (H1N1).Atlanta: US Department of Health and Human Services, CDC; 2009. Available from: http://www.who.int/csr/resources/ publications/swineflu/CDCrealtimeRTPCRprotocol-20090428.pdf Accessed February 19, 2010.
8. Morgan OW, Parks S, Shim T, et al. Transmission of pandemic in-fluenza A (H1N1) 2009 strain in San Antonio Texas, United States, April\May, 2009. Emerg Infect Dis, in press.
9. Centers for Disease Control Prevention. Updated interim recom-mendations: special considerations for clinicians regarding 2009 H1N1 influenza in severely immunosuppressed patients. Atlanta: US Department of Health and Human Services, CDC, 2009. Available from: http://www.cdc.gov/h1n1flu/immunosuppression/index. htm. Accessed February 19, 2010.
10. Kendal AP, Pereira MS, Skehel JJ, Noble GR, Schild GC. Concepts and procedures for laboratory-based influenza surveillance. Atlanta and London: Centers for Disease Control and Prevention and WHO Col-laborating Center for Reference and Research on Influenza. 1982.
11. Centers for Disease Control Prevention. People at high risk of de-veloping flu-related complications. Atlanta: US Department of Health and Human Services, CDC, 2009. Available from: http://cdc.gov/h1n1flu/highrisk.htm. Accessed February 19, 2010.
12. Witkop C, Duffy MR, Macias EA, et al. Novel influenza A (H1N1) out-break at the US Air Force Academy. Am J Prev Med. 2010; 38:121-126.
13. Cao B, Li XW, Mao Y, et al. Clinical features of the initial cases of 2009 pandemic influenza A (H1N1) virus infection in China. N Engl J Med 2009; 361:2507-2517.
14. Ling LM, Chow AL, Lye DC, et al. Effects of early oseltamivir therapy on viral shedding in 2009 pandemic influenza A (H1N1) virus in-fection. Clin Infect Dis. 2010; 50:963-939.
15. Leekha S, Zitterkopf NL, Espy MJ, Smith TF, Thompson RL, Sampathkumar P. Duration of influenza A virus shedding in hospi-talized patients implications for infection control. Infect Control Hosp Epidemiol 2007; 28:1071-1076. (Pubitemid 47345268)
16. Update: drug susceptibility of swine-origin influenza A (H1N1) viruses, April 2009. MMWR Morb Mortal Wkly Rep. 2009; 58:433-435.
17. Aoki FY, Boivin G. Influenza virus shedding: excretion patterns and effects ofantiviral treatment. J Clin Virol 2009; 44:255-261.
18. Boivin G, Goyette N, Hardy I, Aoki F, Wagner A, Trottier S. Rapid antiviral effect of inhaled zanamivir in the treatment of naturally occurring influenza in otherwise healthy adults.J Infect Dis. 2000; 181:1471-1274.
19. Hayden FG, Osterhaus AD, Treanor JJ, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus in-fections. GG167 Influenza Study Group. N Engl J Med 1997; 337:874-880. (Pubitemid 27408569)
20. Hayden FG, Treanor JJ, Fritz RS, et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized con-trolled trials for prevention and treatment JAMA 1999; 282:1240-1246. (Pubitemid 29468495)
21. Puhakka T, Lehti H, Vainionpaa R, et al. Zanamivir: a significant re-duction in viral load during treatment in military conscripts with in-fluenza. Scand J Infect Dis. 2003; 35:52-58. (Pubitemid 36336368)
22. Sato M, Hosoya M, Kato K, Suzuki H. Viral shedding in children with influenza virus infections treated with neuraminidase inhibitors. Pe-diatr Infect Dis J. 2005; 24:931-932. (Pubitemid 41475935)
23. Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA 2000; 283:1016-1024. (Pubitemid 30112215)
24. Nicholson KG, Aoki FY, Osterhaus AD, et al. Efficacy safety of osel-tamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet 2000; 3558:1845-1850. (Pubitemid 30311875)
25. Whitley RJ, Hayden FG, Reisinger KS, et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J. 2001; 20:127-133. (Pubitemid 32151932)
26. Ng S, Cowling BJ, Fang VJ, et al. Effects of oseltamivir treatment on duration of clinical illness and viral shedding and household trans-mission of influenza virus. Clin Infect Dis. 2010; 50:707-714.
27. Kwon YK, Joh SJ, Kim MC, et al. Highly pathogenic avian influenza (H5N1) in the commercial domestic ducks of South Korea. Avian Pathol. 2005; 34:367-370.